– USA, CA – BlackThorn Therapeutics, Inc. today announced the promotion of company co-founder and seasoned CNS drug discovery and development expert, William J. Martin, Ph.D., to CEO and his appointment to the Board of Directors. Dr. Martin has previously served as the company’s president and COO, as well as its chief scientific officer.
“BlackThorn has made important progress in the advancement of its programs to address the current challenges in CNS drug discovery,” said Paul L. Berns, BlackThorn’s executive chairman of the Board of Directors and venture partner at ARCH. “As the company moves into phase 2 development with its lead program, it is invaluable to have Bill’s leadership of the organization. Since BlackThorn’s founding, he has been instrumental in the company’s growth and has made numerous impactful contributions, including developing its state-of-the-art computational psychiatry platform to fuel innovation while advancing a pipeline of targeted therapeutics. On behalf of the Board, we are highly confident in his ability to lead BlackThorn into its next phase of growth as a clinical-stage company and beyond.”
Under Dr. Martin’s stewardship, BlackThorn has engineered pathfinder, a cloud-based computational psychiatry platform that enables multimodal data to be collected, integrated and analyzed at scale. Leveraging pathfinder, the company creates a quantitative, brain-based understanding of neurobehavioral disorders. BlackThorn applies these data-driven insights to create treatments targeted to biologically-based subtypes of patients with the goal of increasing the precision of therapeutic intervention.
BlackThorn expects to begin a phase 2 clinical trial of its lead molecule, BTRX-140, a selective KOR antagonist, by year-end. The company believes that KOR antagonism has the potential to address key drivers of disability, such as depressed mood, anxiety, anhedonia and cognitive impairment, which commonly occur in multiple disorders. The initial phase 2 trial of BTRX-140 will enroll patients with major depressive disorder, who have symptoms of anxiety and anhedonia. The company is also advancing a V1aR antagonist for the potential treatment of autism spectrum disorder and expects to begin a phase 1 trial in early 2020.
About Dr Bill Martin
Prior to joining BlackThorn, Dr. Martin held multiple leadership positions at Theravance Biopharma, including leading the company’s research portfolio planning initiative and serving as a member of the strategic partnership team and project team leader for an advanced clinical-stage CNS program. He began his career at Merck where he contributed to the strategic direction of Merck’s neuroscience franchise and chaired multiple CNS development teams. Dr. Martin serves on the Advisory Council for Brown University’s Carney Institute for Brain Science and is an At-Large Member of the Coalition for the Life Sciences Board of Directors. He is co-chair of the Federal Engagement and Regulatory Affairs Committee of the Alliance for Artificial Intelligence in Healthcare.
“At BlackThorn, our goal is to transform the way we understand and treat neurobehavioral disorders in order to empower affected individuals to live better lives,” said Dr. Martin. “To do this, we have built pathfinder to increase the probability of success in finding the right targets, molecules and well-defined patient subgroups most likely to respond to treatment. I am honored to now take on the CEO role to work alongside the Board and our talented workforce to advance our pipeline of targeted therapeutics. I believe we collectively have the deep domain expertise and operational experience to address historical challenges in CNS drug discovery and bring new medicines to the millions of people in need of better treatment options.”
Dr. Martin graduated from Swarthmore College, earned a Ph.D. from Brown University, and conducted postdoctoral research at the Keck Center for Integrative Neuroscience at the University of California, San Francisco.
About BlackThorn Therapeutics
BlackThorn Therapeutics, Inc., is a clinical-stage, neurobehavioral health company committed to improving the lives of people with neurobehavioral disorders through the discovery and development of novel, targeted therapeutics. Our goal is to empower patients and physicians to make treatment decisions and plans based on an individual’s profile across the spectrum of neurobehavioral health. In order to address historical challenges in CNS drug development, we have engineered pathfinder, a proprietary computational psychiatry platform to capture, quantify and model multiple data types. We use pathfinder to better understand how networks of brain activity related to normal and disordered behavior, and we employ high-performance computing, predictive models and artificial intelligence technology to accelerate the entire process. We apply pathfinder outputs to identify novel targets, small molecule drug candidates and biologically-based patient subgroups. Our lead clinical program is focused on BTRX-140, a selective KOR antagonist, for which a phase 2 trial in major depressive disorder is expected to begin in 4Q:19. Our second clinical program is focused on a selective V1aR antagonist for the potential treatment of autism spectrum disorder, for which a phase 1 trial is expected to begin in early 2020. Both molecules were discovered in collaboration with The Scripps Research Institute. BlackThorn is headquartered in San Francisco, California.
For more information: https://www.blackthornrx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.